Topic 393: Breath Test for Biomarkers of Radiation Exposure

问题：接受治疗性放射治疗的患者面临不良毒副作用的风险。这些不良事件通常是不可预测的，可能会导致严重的发病率或死亡率。例如：三分之一或 更多因肺癌而接受胸部放射治疗的患者可能会患上危及生命的急性放射性肺炎。 临床需要：临床上需要一种客观的测试来评估放射治疗的生物学反应。这样的测试将在早期识别出不良事件风险增加的患者 治疗过程中，并使治疗医生减少辐射剂量。呼气测试-问题的新解决方案：呼气测试可以提供一个合理的工具 评估放射治疗的生物反应，因为辐射会导致组织中的氧化应激，导致呼吸中挥发性有机化合物(VOCs)的排泄。呼吸生物标记物有 在之前的动物和人类研究中，准确地确定了辐射暴露。 BreathX-一种先进的新型呼气测试系统：BreathX是一种快速、经济高效且用户友好的系统，用于检测呼气中的挥发性生物标志物。呼吸X使用超清洁气球来 采集呼气样本，用相对便宜的桌面气相色谱仪进行分析。BreathX提供了一个新的机会，可以快速测试对辐射的生物反应，并可能识别有不良毒性影响的患者。 建议的研究：我们将验证BreathX呼气测试作为一种新的工具来评估对辐射的生物反应。短期目标(阶段1)是在动物身上和在 体外研究。长期目标(第2阶段)是在接受治疗性放射治疗的患者中验证这项测试，以便估计他们对辐射的生物反应，并识别那些不良事件风险增加的人。 这项研究的潜在好处：在放射治疗的早期阶段进行呼吸X呼气测试可以识别出不良反应风险增加的患者。通过提醒医生采用 根据减少剂量计划，BreathX呼气测试可以通过降低患者的死亡率和发病率而使患者受益，还可以通过降低不良反应可能导致的成本而使医疗保健系统受益。

The problem: Patients receiving therapeutic radiation are at risk of adverse toxic effects. These adverse events are usually unpredictable and may result in severe morbidity or mortality. Example: A third or more of patients receiving chest radiation for cancers of lung may develop life-threatening acute radiation pneumonitis. The clinical need: There is a clinical need for an objective test to estimate the biologic response to therapeutic radiation. Such a test would identify patients at increased risk of an adverse event early in the course of treatment, and enable the treating physician to reduce the radiation dosage. Breath testing - a new solution to the problem: Breath testing could provide a rational tool to estimate the biologic response to radiation therapy, because radiation causes oxidative stress in tissues, resulting in the excretion of volatile organic compounds (VOCs) in the breath. Breath biomarkers have accurately identified exposure to radiation in previous animal and human studies. BreathX - an advanced new breath testing system: Breath X is a rapid, cost-effective and userfriendly system for detection of volatile biomarkers in breath. Breath X employs ultra-clean balloons for collection of breath samples that are analyzed with a comparatively inexpensive tabletop gas chromatograph. BreathX offers a new opportunity to rapidly test for biological response to radiation and potentially identify patients at risk of adverse toxic effects. Proposed research: We will validate the BreathX breath test as a new tool to estimate biological response to radiation. The short-term objective (Phase 1) is to demonstrate proof of principle in animals and in in-vitro studies. The long-term objective (Phase 2) is to validate the test in patients receiving therapeutic radiation in order to estimate their biologic response to radiation and to identify those at increased risk of an adverse event. Potential benefits of the research: A BreathX breath test during the earliest stage of therapeutic radiation could identify patients at increased risk of an adverse response. By alerting the physician to adopt a reduced dosage plan, a BreathX breath test could benefit patients by reducing their risk of mortality and morbidity, and also benefit the healthcare system by reducing the costs that would have resulted from adverse responses.